1.32
0.16 (13.79%)
| Previous Close | 1.16 |
| Open | 1.17 |
| Volume | 8,841,631 |
| Avg. Volume (3M) | 4,222,219 |
| Market Cap | 412,242,272 |
| Price / Sales | 64.90 |
| Price / Book | 109.49 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2025 |
| Operating Margin (TTM) | -979.14% |
| Diluted EPS (TTM) | -0.200 |
| Quarterly Revenue Growth (YOY) | 46.10% |
| Total Debt/Equity (MRQ) | 199.97% |
| Current Ratio (MRQ) | 2.60 |
| Operating Cash Flow (TTM) | -50.90 M |
| Levered Free Cash Flow (TTM) | -27.58 M |
| Return on Assets (TTM) | -61.33% |
| Return on Equity (TTM) | -248.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Ocugen, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA"). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.60% |
| % Held by Institutions | 26.48% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gmt Capital Corp | 30 Jun 2025 | 4,153,798 |
| Cubist Systematic Strategies, Llc | 30 Jun 2025 | 1,666,707 |
| Rinkey Investments | 30 Jun 2025 | 1,179,006 |
| Summittx Capital, L.P. | 30 Jun 2025 | 639,200 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (Chardan Capital, 430.30%) | Buy |
| 7.00 (HC Wainwright & Co., 430.30%) | Buy | |
| Median | 7.00 (430.30%) | |
| Average | 7.00 (430.30%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.02 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 04 Aug 2025 | 7.00 (430.30%) | Buy | 1.00 |
| 24 Jun 2025 | 7.00 (430.30%) | Buy | 1.04 | |
| HC Wainwright & Co. | 24 Jun 2025 | 7.00 (430.30%) | Buy | 1.04 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |